Switching

Switching From Wegovy to Zepbound: Key Considerations

GLP-1 Companion · 8 min read

Switching from Wegovy to Zepbound is one of the more clinically significant medication changes a patient can make in the GLP-1 space. Unlike switching between two formulations of semaglutide, this transition involves moving from a GLP-1 receptor agonist to a dual GLP-1 and GIP receptor agonist — a meaningfully different mechanism of action. That difference has real implications for how the transition is managed, what side effects to expect, and what the long-term outcomes data suggests.

Why This Switch Is Different

Semaglutide (Wegovy) acts exclusively on GLP-1 receptors, mimicking the natural incretin hormone GLP-1 to slow gastric emptying, reduce appetite, and improve insulin sensitivity. Tirzepatide (Zepbound) adds agonism at the GIP (glucose-dependent insulinotropic polypeptide) receptor, which further enhances insulin secretion, modulates fat metabolism, and may contribute to a distinct tolerability profile. Because these are different molecules binding to different — though overlapping — receptor systems, the body's response to tirzepatide is not simply a continuation of semaglutide therapy. It requires a fresh start at the bottom of the dose ladder.

Starting at the Lowest Dose

When switching from Wegovy to Zepbound, clinical practice guidelines and manufacturer labeling consistently recommend beginning at tirzepatide 2.5 mg per week — the starting dose — regardless of the semaglutide dose you were taking. A patient who had worked up to Wegovy 2.4 mg and tolerated it well still begins Zepbound at 2.5 mg. This approach is not a reflection of your prior tolerance; it is because tirzepatide at any dose is a new molecular interaction that requires its own titration period.

Is a Washout Period Needed?

The washout period question is among the most common that patients ask, and the answer in most cases is no. There is no clinical evidence requiring a gap between stopping Wegovy and starting Zepbound. Both medications have weekly dosing and similar half-lives (semaglutide approximately one week, tirzepatide approximately five days). In practice, the transition typically happens on what would have been the next scheduled injection day — you simply inject Zepbound instead of Wegovy. However, if you experienced a serious adverse event on Wegovy — such as pancreatitis or severe gastroparesis — your provider may want a period of observation before initiating the new agent.

GI Side Effects May Reset

Even if you had fully adapted to Wegovy with minimal side effects, switching to Zepbound commonly brings a return of nausea, bloating, or loose stools during the first several weeks of titration. This is not a sign that tirzepatide is less tolerable — it reflects the body adjusting to a new molecule and new dose. Most patients who experience side effects during the initial tirzepatide titration find that they resolve within the first four to eight weeks, just as they did when starting semaglutide. Eating smaller, lower-fat meals and avoiding alcohol helps manage the transition period.

What the SURMOUNT-5 Trial Shows

SURMOUNT-5, published in the New England Journal of Medicine in early 2025, was the first head-to-head randomized trial comparing tirzepatide directly to semaglutide 2.4 mg for chronic weight management. The results were unambiguous: tirzepatide produced substantially greater weight loss. At 72 weeks, participants on tirzepatide achieved a mean body weight reduction of approximately 20.2% compared to 13.7% for semaglutide — a difference of about 6.5 percentage points. Tirzepatide was also associated with significantly greater reductions in waist circumference and a higher proportion of participants achieving 20% or greater weight loss.

Importantly, SURMOUNT-5 also found that tirzepatide had a lower discontinuation rate due to adverse events compared to semaglutide in this trial population. This challenges the perception that tirzepatide is harder to tolerate, though individual experiences vary considerably.

Insurance and Formulary Considerations

Insurance coverage for Zepbound for obesity is not automatic, even for patients already approved for Wegovy. The two medications are manufactured by different companies, sit on different formulary tiers at most insurers, and require separate prior authorizations. Your provider will need to submit a new prior auth for Zepbound documenting your BMI, comorbidities, and the clinical rationale for the switch. If your plan covers Wegovy but not Zepbound, or vice versa, this may be a deciding factor in whether the switch is financially viable.

• Check your insurer's formulary for Zepbound before initiating the switch request.
• Eli Lilly offers a Zepbound savings card that reduces costs to as low as $25 to $550 per month for eligible commercially insured patients.
• Medicare Part D plans have increasingly added Zepbound coverage following its 2024 CMS inclusion.
• If denied, request a peer-to-peer review where your physician speaks directly with the insurer's medical director.
• Ask whether a step-therapy requirement (proving failure on another agent) applies — your Wegovy history may satisfy this.

Re-Escalation Timeline

The standard tirzepatide titration schedule moves up every four weeks as tolerated: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Most patients reach their maintenance dose — often 10 mg or 15 mg — within 20 to 24 weeks. This means that for the first five to six months after the switch, you will be below the maximum effective dose. Some patients who were getting good results on Wegovy 2.4 mg may temporarily lose some momentum during this titration phase. This is expected and does not mean the switch is not working.

What to Expect in the First Weeks

The first four weeks at tirzepatide 2.5 mg are often the most challenging. The dose is low, appetite suppression is modest, and any weight that returns during the titration period can feel discouraging. It is useful to frame this phase as an investment — your body is adapting to the new medication, and the full therapeutic effect will build over several months. Tracking non-scale victories like waist measurements, energy levels, and hunger patterns can be helpful during this period.

Data from SURMOUNT-5 demonstrated that patients on tirzepatide were about 50% more likely to achieve at least 25% total body weight loss compared to semaglutide. For many patients, the re-escalation period is a temporary step back before a more substantial long-term gain.

Key Takeaways

Switching from Wegovy to Zepbound requires restarting at tirzepatide 2.5 mg, regardless of your previous semaglutide dose. No washout period is typically needed. Expect GI side effects to temporarily return during titration. The head-to-head SURMOUNT-5 data favors tirzepatide for weight loss outcomes. Insurance authorization must be secured independently of your Wegovy coverage. The titration process takes approximately five to six months to reach maintenance dosing. Work closely with your provider to manage expectations and monitor your progress throughout the transition.

Sources

• Wegovy (semaglutide) Prescribing Information. Novo Nordisk.
• Zepbound (tirzepatide) Prescribing Information. Eli Lilly.